Secondary prevention after ischemic stroke or transient ischemic attack.

[1]  V. Chair,et al.  Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. , 2014, Stroke.

[2]  M. Wintermark,et al.  Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association , 2013, Stroke.

[3]  Mark D. Huffman,et al.  Heart disease and stroke statistics--2013 update: a report from the American Heart Association. , 2013, Circulation.

[4]  E. V. Simon.  Beta-Blocker Use and Clinical Outcomes in Stable Outpatients With and Without Coronary Artery Disease , 2013 .

[5]  Deepak L. Bhatt,et al.  β-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. , 2012, JAMA.

[6]  R. Felberg,et al.  Closure or medical therapy for cryptogenic stroke with patent foramen ovale. , 2012, The New England journal of medicine.

[7]  Eric E. Smith,et al.  Data quality in the American Heart Association Get With The Guidelines-Stroke (GWTG-Stroke): results from a national data validation audit. , 2012, American heart journal.

[8]  Sean I. Savitz,et al.  Stenting versus Aggressive Medical Therapy for Intracranial Arterial Stenosis , 2012 .

[9]  B. Ovbiagele,et al.  Impact of a healthy lifestyle on all-cause and cardiovascular mortality after stroke in the USA , 2011, Journal of Neurology, Neurosurgery & Psychiatry.

[10]  D. Atar,et al.  Apixaban versus warfarin in patients with atrial fibrillation. , 2011, The New England journal of medicine.

[11]  Deepak L. Bhatt,et al.  Two-Year Vascular Event Rates in Patients with Symptomatic Cerebrovascular Disease: The REACH Registry , 2011, Cerebrovascular Diseases.

[12]  Karen L. Furie,et al.  Response to Letter by Naylor Regarding Article, “Guidelines for the Prevention of Stroke in Patients With Stroke or Transient Ischemic Attack: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association” , 2011 .

[13]  Jun Zhu,et al.  Apixaban in patients with atrial fibrillation. , 2011, The New England journal of medicine.

[14]  A. Khera,et al.  Forecasting the Future of Cardiovascular Disease in the United States: A Policy Statement From the American Heart Association , 2011, Circulation.

[15]  D. Jatužis,et al.  The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo-controlled, double-blind trial , 2011, The Lancet.

[16]  R. Troughton,et al.  Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. , 2011, The New England journal of medicine.

[17]  Irene Katzan,et al.  Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the american heart association/american stroke association. , 2011, Stroke.

[18]  Short-term outcome after stenting versus endarterectomy for symptomatic carotid stenosis: a preplanned meta-analysis of individual patient data , 2010, The Lancet.

[19]  Deepak L. Bhatt,et al.  Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis. , 2010, JAMA.

[20]  S. Yusuf,et al.  Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study , 2010, The Lancet.

[21]  Michael D Hill,et al.  Stenting versus endarterectomy for treatment of carotid-artery stenosis. , 2010, The New England journal of medicine.

[22]  A. Rabinstein.  Aspirin vs anticoagulation in carotid artery dissection: A study of 298 patients , 2010 .

[23]  S. Yusuf,et al.  Dabigatran versus warfarin in patients with atrial fibrillation. , 2009, The New England journal of medicine.

[24]  Deepak L. Bhatt,et al.  Three-year follow-up and event rates in the international REduction of Atherothrombosis for Continued Health Registry , 2009, European heart journal.

[25]  L. Mascitelli,et al.  HEMORRHAGIC STROKE IN THE STROKE PREVENTION BY AGGRESSIVE REDUCTION IN CHOLESTEROL LEVELS STUDY , 2009, Neurology.

[26]  P. Rothwell,et al.  Effect of urgent treatment for transient ischaemic attack and minor stroke on disability and hospital costs (EXPRESS study): a prospective population-based sequential comparison , 2009, The Lancet Neurology.

[27]  Li Liang,et al.  Get With the Guidelines–Stroke Is Associated With Sustained Improvement in Care for Patients Hospitalized With Acute Stroke or Transient Ischemic Attack , 2009, Circulation.

[28]  W. Elliott.  Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: Meta-analysis of randomised trials , 2009 .

[29]  S. Bangalore,et al.  β‐blockers as fourth‐line therapy for hypertension: stay the course , 2008, International journal of clinical practice.

[30]  S. Yusuf,et al.  Telmisartan to prevent recurrent stroke and cardiovascular events. , 2008, The New England journal of medicine.

[31]  Vivian Gu,et al.  Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. , 2008, The New England journal of medicine.

[32]  B. Dimitrov,et al.  Major Vascular Events after Transient Ischaemic Attack and Minor Ischaemic Stroke: Post Hoc Modelling of Incidence Dynamics , 2008, Cerebrovascular Diseases.

[33]  P. Rothwell,et al.  Risk of stroke early after transient ischaemic attack: a systematic review and meta-analysis , 2007, The Lancet Neurology.

[34]  M. Hennerici,et al.  Effects of Intense Low-Density Lipoprotein Cholesterol Reduction in Patients With Stroke or Transient Ischemic Attack: The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Trial , 2007, Stroke.

[35]  A. Demchuk,et al.  Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a randomised controlled pilot trial , 2007, The Lancet Neurology.

[36]  S. Gutnikov,et al.  Effect of urgent treatment of transient ischaemic attack and minor stroke on early recurrent stroke (EXPRESS study): a prospective population-based sequential comparison , 2007, The Lancet.

[37]  S. Bangalore,et al.  A meta-analysis of 94,492 patients with hypertension treated with beta blockers to determine the risk of new-onset diabetes mellitus. , 2007, The American journal of cardiology.

[38]  M. Aguilar,et al.  Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation , 2007, Annals of Internal Medicine.

[39]  A. Dominiczak,et al.  2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) , 2007, European heart journal.

[40]  J. Spence,et al.  Combining Multiple Approaches for the Secondary Prevention of Vascular Events After Stroke: A Quantitative Modeling Study , 2007, Stroke.

[41]  Piotr Ponikowski,et al.  2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). , 2007, European heart journal.

[42]  Deepak L. Bhatt,et al.  One-year cardiovascular event rates in outpatients with atherothrombosis. , 2007, JAMA.

[43]  A. Algra,et al.  Medium intensity oral anticoagulants versus aspirin after cerebral ischaemia of arterial origin (ESPRIT): a randomised controlled trial , 2007, The Lancet Neurology.

[44]  C. Mathers,et al.  Preventing stroke: saving lives around the world , 2007, The Lancet Neurology.

[45]  A. Waldo.  Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trialConnolly SJ, for The ACTIVE Writing Group for the ACTIVE Investigators (Hamilton Health , 2007 .

[46]  J. Farmer.  High-dose atorvastatin after stroke or transient ischemic attack. , 2007, Current atherosclerosis reports.

[47]  Xavier Ducrocq,et al.  Endarterectomy versus stenting in patients with symptomatic severe carotid stenosis. , 2006, The New England journal of medicine.

[48]  W. Hacke,et al.  30 day results from the SPACE trial of stent-protected angioplasty versus carotid endarterectomy in symptomatic patients: a randomised non-inferiority trial , 2006, The Lancet.

[49]  L. Wong.  Global Burden of Intracranial Atherosclerosis , 2006, International journal of stroke : official journal of the International Stroke Society.

[50]  Patrice Cacoub,et al.  Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. , 2006, The New England journal of medicine.

[51]  Deepak L. Bhatt,et al.  International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. , 2006, JAMA.

[52]  S. Gutnikov,et al.  Population-based study of event-rate, incidence, case fatality, and mortality for all acute vascular events in all arterial territories (Oxford Vascular Study) , 2005, The Lancet.

[53]  H. Diener,et al.  Morbidity and Mortality After Stroke, Eprosartan Compared With Nitrendipine for Secondary Prevention: Principal Results of a Prospective Randomized Controlled Study (MOSES) , 2005, Stroke.

[54]  S. Kasner,et al.  Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. , 2005, The New England journal of medicine.

[55]  P. Rothwell,et al.  Timing of TIAs preceding stroke , 2005, Neurology.

[56]  H. Diener,et al.  Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial , 2004, The Lancet.

[57]  G. Donnan,et al.  Atheroma of the aortic arch: an important and poorly recognised factor in the aetiology of stroke , 2004, The Lancet Neurology.

[58]  J. Tu,et al.  The high risk of stroke immediately after transient ischemic attack , 2004, Neurology.

[59]  M. Eliasziw,et al.  Endarterectomy for symptomatic carotid stenosis in relation to clinical subgroups and timing of surgery , 2004, The Lancet.

[60]  R. Collins,et al.  Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20 536 people with cerebrovascular disease or other high-risk conditions , 2004, The Lancet.

[61]  J. Leonardi-Bee,et al.  Blood Pressure Reduction and Secondary Prevention of Stroke and Other Vascular Events: A Systematic Review , 2003, Stroke.

[62]  S. Gutnikov,et al.  Analysis of pooled data from the randomised controlled trials of endarterectomy for symptomatic carotid stenosis , 2003, The Lancet.

[63]  A. Mattioli,et al.  Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients , 2002, BMJ : British Medical Journal.

[64]  J. Coste,et al.  Recurrent cerebrovascular events associated with patent foramen ovale, atrial septal aneurysm, or both. , 2001, The New England journal of medicine.

[65]  David B. Matchar,et al.  Improving the Reliability of Stroke Subgroup Classification Using the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) Criteria , 2001, Stroke.

[66]  S. Sidney,et al.  Short-term prognosis after emergency department diagnosis of TIA. , 2000, JAMA.

[67]  S. Yusuf,et al.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. , 2000 .

[68]  C. Wolfe,et al.  The impact of stroke. , 2000, British medical bulletin.

[69]  J. Kirkpatrick,et al.  Benefit of carotid endarterectomy in patients with symptomatic moderate or severe stenosis. , 1998, Journal of insurance medicine.

[70]  David Schultz,et al.  A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE) , 1996, The Lancet.

[71]  A. Algra,et al.  Aspirin at any dose above 30 mg offers only modest protection after cerebral ischaemia. , 1996, Journal of neurology, neurosurgery, and psychiatry.

[72]  Eaft Study Group.  Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke , 1993, The Lancet.

[73]  C. Warlow,et al.  MRC European Carotid Surgery Trial: interim results for symptomatic patients with severe (70-99%) or with mild (0-29%) carotid stenosis , 1991, The Lancet.

[74]  A. Lowenthal.  The European Stroke Prevention Study , 1988, Acta neurologica Belgica.